Q3 2023 Results

Company overview Financial review Conclusions Appendix References Remibrutinib - opportunity for efficacious oral therapy with fast onset of action¹ after antihistamines INNOVATION Remibrutinib, a highly selective oral BTKi WW: 40m CSU patients²; US: ~1.1m treated adults with CSU³ Antihistamines CSU treatment gap Biologics ~600k³ patients controlled with SoC4 ~400k³ patients not controlled with SoC4 Only ~80k3 patients treated with biologics High unmet need after antihistamines Opportunity for Remibrutinib HCP Healthcare professional. CSU Chronic spontaneous urticaria. SOC Standard of care. 1. As illustrated by a higher proportion of patients achieving UAS7≤6 at Week 2 in the REMIX-1 and REMIX-2 studies when treated with remibrutinib compared to placebo. 2. Maurer M, Weller K, Bindslev-Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011;66:317-330 and The World Bank. Population, total. Available from: https://data.worldbank.org/indicator/SP.POP.TOTL [Last accessed: July 2023]. 3. US only Novartis internal analysis. 4. H1, H2 antihistamines and antihistamines escalation. 18 Investor Relations | Q3 2023 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation